Dexcom- a company that has become synonymous with continuous glucose monitor systems for many diabetics, presented proof at the American Diabetes Association’s 77th Scientific confrence ,that CGM therapy helps both type 1 and type 2 people living with diabetes on multiple daily injections.
The Food and Drug Administration approved Dexcom’s
G5 mobile application for use on the Android platform. This is important because Dexcom’s G5 technology makes conventional CGM receivers less necessary because the blood glucose data can be transmitted directly to a smart phone.
Dexcom’s President & CEO Kevin Sayer speaks to Nadia Al-Samarrie about these finding and the future of continous glucose monitoring.